Spears Abacus Advisors LLC Gritstone Bio, Inc. Transaction History

Spears Abacus Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.46 - $4.75 $29,050 - $56,092	11,809 New	11,809 $30,000
Q2 2021 Aug 09, 2021	SELL	$8.13 - $10.2 $10,162 - $12,750	-1,250 Reduced 9.39%	12,064 $110,000
Q1 2021 May 14, 2021	SELL	$4.07 - $27.11 $61,318 - $408,439	-15,066 Reduced 53.09%	13,314 $126,000
Q4 2020 Feb 12, 2021	SELL	$2.57 - $4.22 $11,205 - $18,399	-4,360 Reduced 13.32%	28,380 $112,000
Q3 2020 Nov 16, 2020	SELL	$2.63 - $8.09 $95,705 - $294,395	-36,390 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$5.69 - $8.17 $115,848 - $166,341	20,360 Added 127.01%	36,390 $242,000
Q4 2019 Feb 14, 2020	BUY	$7.07 - $11.61 $113,332 - $186,108	16,030 New	16,030 $144,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Spears Abacus Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Spears Abacus Advisors LLC with notifications on news.